Order Article Reprints

Bellio H, Bertaut A, Hervieu A, Zanetta S, Hennequin A, Vincent J, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Fumet J-D. Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. Cancers. 2021; 13(21):5472. https://doi.org/10.3390/cancers13215472

Bellio, Hélène, Aurélie Bertaut, Alice Hervieu, Sylvie Zanetta, Audrey Hennequin, Julie Vincent, Rémi Palmier, Leila Bengrine-Lefevre, François Ghiringhelli, and Jean-David Fumet. 2021. "Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer" Cancers 13, no. 21: 5472. https://doi.org/10.3390/cancers13215472

Bellio, H., Bertaut, A., Hervieu, A., Zanetta, S., Hennequin, A., Vincent, J., Palmier, R., Bengrine-Lefevre, L., Ghiringhelli, F., & Fumet, J.-D. (2021). Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. Cancers, 13(21), 5472. https://doi.org/10.3390/cancers13215472